KR-39038 is an orally effective GRK5 (G protein-coupled receptor kinase 5) inhibitor with an IC50 of 0.02 μM; it exhibits significant anti-cardiac hypertrophy effects and improves cardiac function by inhibiting the HDAC5 pathway and attenuating angiotensin II-induced cardiomyocyte hypertrophy in neonatal cardiomyocytes; it can be used in the research of heart failure.